20/20 Biolabs, Inc. cotiza a 0.37 USD y tiene una capitalización bursátil de $5M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the…
| Periodo | 2026-05 |
|---|---|
| Real | $-0.28 |
| Estimado | $-0.10 |
| Sorpresa | -180.0% |
| Métrica | AIDX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 29.6% | 57.0% | -27.5% |
| Operating Margin | -162.9% | -38.6% | -124.3% |
| Net Margin | -182.8% | -33.6% | -149.3% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -90.4% | -32.0% | -58.4% |
| Current Ratio | 0.60 | 2.84 | -2.24 |
| Debt / Equity | — | 0.28 | — |